

HF HEART FAILURE FACT SHEET

30-DAY MEASURES

Get With The GuidelinesSM - Heart Failure (GWTG-HF) is the American Heart Association's (AHA's) collaborative quality improvement program, demonstrated to improve adherence to evidence-based care of patients hospitalized with heart failure.

The program provides hospitals with a Web-based Patient Management ToolTM (powered by Outcome Sciences, Inc.), decision support, robust registry, real-time benchmarking capabilities and other performance improvement methodologies toward the goal of enhancing patient outcomes and saving lives.

To further support the continuity of care for those patients discharged from the hospital, the AHA created the 30-day follow-up form. This form allows hospitals to capture patient data in the 30-day period after hospitalization, such as mortality, re-hospitalization, follow-up visits, medication adherence, rehabilitation, patient education, etc.

THE BENEFITS OF THE 30-DAY FORM ARE THAT IT:

- **Ensures consistency:** The form allows for the collection of 30-day post-discharge information in a consistent fashion from hospital to hospital.
- **Avoids duplication:** The form reduces administrative burden by auto-populating relevant fields from the PMT.
- **Allows for flexibility:** The form includes only a few mandatory fields, but provides access to numerous optional fields,
- **Provides real-time feedback:** The form allows hospitals to determine how they are doing on high-interest data elements.

HEART FAILURE 30-DAY MEASURES

- **30-day ACEI/ARBs:** Percent of heart failure patients with left ventricular systolic dysfunction (LVSD) and without both ACEI and ARB contraindications who are on an ACEI or ARB 30 days post discharge. For the purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular function (LVF) consistent with moderate or severe systolic dysfunction.
- **30-day aldosterone antagonist:** Percent of heart failure patients with LVSD with no contraindications or documented intolerance who were prescribed aldosterone antagonist 30 days post discharge.

- **30-day beta-blocker for LVSD:** Percent of heart failure patients on beta-blocker 30 days post discharge.
- **30-day hydralazine nitrate for LVSD:** Percent of black heart failure patients with LVSD with no contraindications or documented intolerance who were prescribed a hydralazine nitrate 30 days post discharge.
- **30-day lipid-lowering medication:** Percent of heart failure patients with either CAD, PVD, CVA, or diabetes who were prescribed lipid-lowering medications 30 days post discharge.
- **30-day diabetic Tx:** Percent of patients receiving diabetic treatment 30 days post discharge.
- **30-day re-hospitalization:** Percent of heart failure patients (unadjusted) with one or more re-hospitalization in the first 30 days post discharge.
- **30-day mortality post discharge:** Percent of heart failure patients who died in the first 30 days post discharge.
- **30-day mortality:** Percent of heart failure patients (unadjusted) who died in the first 30 days since admission, including in-hospital deaths.